Increasing the Therapeutic Window of Engineered Interleukin-2 & Driving Expansion of Antigen-Specific Regulatory T cells with ImmTOR Tolerogenic Nanoparticles
Time: 12:30 pm
day: Day One AM Non-Cell Based Approaches
Details:
- IL-2 can be engineered to increase its half-life and selectivity for Tregs; however, selectivity can be reduced at higher doses and in settings of activated effector cells
- ImmTOR nanoparticles loaded with rapamycin acts synergistically with engineered IL-2 to increase expansion Tregs while mitigating effector cell activation
- Engineered IL-2 combined with ImmTOR also acts synergistically to enhance induction of antigen-specific Tregs for protection against autoimmune disease
